On Sep 18, we issued an updated research report on Insulet Corporation PODD. Although the company’s achievement of two milestones with respect to expansion of Omnipod’s market reach makes us optimistic, a tough competitive landscape raises concern. The stock currently carries a Zacks Rank #3 (Hold).
Shares of this leading developer, manufacturer and marketer of the Omnipod Insulin Management System have been outperforming its industry over the past three months. The stock has gained 16.4% compared with the industry’s 7.6% rise. Insulet exited the second quarter with better-than-expected figures.
Insulet exited the second quarter of 2020 with better-than-expected figures. Revenues improved significantly on the solid uptake of the Omnipod system, both in the United States and the international markets. This growth amid the crisis was primarily due to record revenue growth in total Omnipod product line along with growth in other segments. The momentum of Omnipod DASH is encouraging based on the solid uptake in geographies in which it has been launched. The company’s plans of geographical expansion buoy optimism.
Insulet Corporation Price
The company is gradually improving with respect to seamless supply chain and manufacturing operations. It has also added significant capacity in preparation for the Omnipod 5 launch in 2021. Despite coronavirus impact, Insulet expects to grow total Omnipod revenues by 18% to 20% in 2020. Also, assuming market dynamics to normalize early next year, Insulet believes that it can maintain its $1 billion revenue goal for 2021.
Insulet’s efforts to minimize supply disruptions during the pandemic are noteworthy. The sales calls are being conducted through Webex. The manufacturing and supply teams are ensuring that growing customer demand is met with minimum disruptions. It has also broadened its financial assistance program to ensure that customers who rely on Omnipod are able to continue using it even if they lose insurance coverage. According to Insulet, it does not expect the coronavirus impact to last for more than a couple of quarters.
However, we are concerned about the slowdown in new Omnipod uptake globally since March due to the deferral of non-emergency physician visits due to COVID-19. Contraction in gross margin is discouraging as well.
Insulet operates in a highly competitive environment, dominated by firms ranging from large multinational corporations with significant resources to start-ups. Also, the stiff rivalry and regulatory conditions prevalent in the markets where Insulet operates limit its ability to switch to strategies like price increases. The company’s Omnipod System primarily contests with Medtronic plc’s market-leading MiniMed system.
Also, the company is exposed to risks associated with a weaker global economy and lower reimbursement rates.
QIAGEN’s long-term earnings-growth rate is estimated at 22.3%. It currently sports a Zacks Rank #1. (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings-growth rate is estimated at 15%. It currently carries a Zacks Rank #2 (Buy).
Hologic’s long-term earnings-growth rate is estimated at 15.5%. The company presently sports a Zacks Rank #1.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.
The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis Report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
Insulet Corporation (PODD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.